Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network
European Journal of Internal Medicine · 2026
DOI: 10.1016/j.ejim.2026.106751 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Internal Medicine, 2026. Verfasst von Michele Rossi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverp…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Kidney Transplantation, Vitamin K, Anticoagulants. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, National Institute for Health and Care Research.
Abstract (Originalsprache)
BACKGROUND: The risk-benefit profile of direct oral anticoagulants (DOACs) in kidney transplant recipients (KTRs) with atrial fibrillation (AF) remains under-investigated. PURPOSE: To evaluate the safety and efficacy of DOACs compared with vitamin K antagonists (VKAs) in KTRs with AF. METHODS: Retrospective analysis from TriNetX network. Adult KTRs with AF were included. Patients with mechanical valves, antiphospholipid syndrome, or an estimated eGFR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Life Health & Environmental Science…
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Division Department of Biomedical Metabolic and N…
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Internal Vascular and Emergency Medicine Stroke U…
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Basic Science, Prince Sultan Bin Ab…
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Nephrology, Liverpool University Ho…
Förderung
- Horizon 2020 Framework Programme
- National Institute for Health and Care Research
Zitieren
APA
Rossi, M., Tartaglia, E., Askarinejad, A., Rigutini, A. G., Alobaida, M., Rao, A., Oni, L., Ferri, C., Bucci, T., & Lip, G. Y. H. (2026). Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2026.106751
Vancouver
Rossi M, Tartaglia E, Askarinejad A, Rigutini AG, Alobaida M, Rao A, et al. Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network. European Journal of Internal Medicine. 2026. doi:10.1016/j.ejim.2026.106751
BibTeX
@article{Rossi2026,
author = {Rossi, Michele and Tartaglia, Enrico and Askarinejad, Amir and Rigutini, Andrea Galeazzo and Alobaida, Muath and Rao, Anirudh and Oni, Louise and Ferri, Claudio and Bucci, Tommaso and Lip, Gregory Y H},
title = {Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network},
journal = {European Journal of Internal Medicine},
year = {2026},
doi = {10.1016/j.ejim.2026.106751}
}
EUVIMED